|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
|
|---|---|---|---|---|---|---|---|---|
| Current assets | ||||||||
| Cash | ||||||||
| Prepaid income tax | ||||||||
| Prepaid expenses | ||||||||
| Total Current Assets | ||||||||
| Deferred offering costs | ||||||||
| Long-term prepaid insurance | ||||||||
| Investments held in Trust Account | ||||||||
| TOTAL ASSETS | ||||||||
| Current liabilities | ||||||||
| Accounts payable and accrued expenses | ||||||||
| Accrued offering costs | ||||||||
| Income tax payable | ||||||||
| Promissory notes - related party | ||||||||
| Total Current Liabilities | ||||||||
| Deferred underwriting fee | ||||||||
| Deferred underwriting fee | ||||||||
| TOTAL LIABILITIES | ||||||||
| Common Stock Subject to Possible Redemption (Notes 2 and 7) | ||||||||
| Common stock subject to possible redemption, 6,900,000 shares issued and outstanding at redemption value of $10.52 and $10.35 per share as of June 30, 2026 and December 31, 2025, respectively | ||||||||
| STOCKHOLDERS’ DEFICIT | ||||||||
| Common stock, $0.0001 par value; 40,000,000 shares authorized; 2,685,750 shares issued and outstanding (excluding 6,900,000 shares subject to possible redemption) at June 30, 2026 and December 31, 2025, respectively | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ||||||||
| Total Stockholders’ Deficit | ||||||||
| TOTAL LIABILITIES, COMMON STOCK SUBJECT TO POSSIBLE REDEMPTION AND STOCKHOLDERS’ DEFICIT |
Loading...
